Tags : Christian Wyss

Deal & transactions

VISCHER advises Versantis on its sale to Gentif

Versantis, a private Swiss-based clinical stage biotechnology company focused on addressing the growing unmet medical needs in liver diseases, is to be sold to Genfit. With this acquisition, Genfit intends to expand its product portfolio with a Phase 2 ready programme based on first-in-class scanning liposome technology, a paediatric programme focused on urea cycle disorder […]

Deal & transactions

VISCHER advises Novaremed on its agreement with NeuroFront

Novaremed, a privately held clinical-stage biopharmaceutical company and NeuroFront Therapeutics, a China-based clinical stage neuroscience biotech company, jointly announced the signing of an exclusive collaboration and commercialization agreement for non-opioid investigational drug, NRD.E1. The Novaremed’s innovative non-opioid drug is being developed for the treatment of diabetes-related neuropathic pain and other neuropathic pain indications. Under the […]

Banking & Finance

Anaveon to raise CHF 110 million in Series B Financing.

Anaveon, a Swiss clinical-stage immuno-oncology company, has agreed to a CHF 110 million Series B financing led by incoming investor Forbion, corner-stoned by founding investor Syncona, also joined by existing investor Novartis Venture Fund, as well as new investors, Cowen Healthcare Investments (a division of Cowen Investment Management), Pfizer Ventures and Pontifax. In connection with […]

Deal & transactions

Polyphor signs merger agreement with EnBiotix. The advisors

EnBiotix, a Boston-based biotech company focused on rare diseases, is merging with Swiss oncology and antimicrobial resistance-focused company Polyphor. A merger agreement under which Polyphor will use all of EnBiotix’s outstanding share capital in exchange for Polyphor Shares was signed.  Polyphor will be renamed and is expected to trade under a new ticker symbol on the Swiss Stock Exchange.  EnBiotix is also acquiring inhaled murepavadin for an agreed value of USD 10 million […]

Deal & transactions

Combioxin signs licensing agreement with Eagle Pharmaceuticals. The advisors 

Combioxin, a clinical phase biotechnology company based in Epalinges, Switzerland, has signed a worldwide commercial license agreement with Eagle Pharmaceuticals, a fully integrated pharmaceutical company based in Woodcliff Lake, NY, USA.  Under the terms of the agreement, Eagle Pharmaceuticals will be solely responsible for the continued clinical development of CAL02 and will provide an upfront payment, […]

Banking & Finance

Vischer advises Haya Therapeutics on completion of Seed Financing Round

Vischer acted as legal counsel for Haya Therapeutics, a company developing precision medicines that target tissue and cell-specific long non-coding RNAs (lncRNAs), on the closing of its CHF 18 million seed round. The financing was led by Broadview Ventures, with participation from Apollo Health Ventures, BERNINA BioInvest, 4See Ventures, Schroder Adveq and Viva BioInnovator. Vischer […]

Deal & transactions

Vischer in the the sale of Mestex AG to Grünenthal

Vischer advised the sellers of Mestex AG on all legal issues related to the sale of their shares and stock options to the pharmaceutical company Grünenthal, a global operator in pain management and related diseases. With the acquisition, Grünenthal aims to grow in the global market for osteoarthritis drugs and further strengthen its pain treatment-focused […]

Deal & transactions

VISCHER advised Snyk on the Swiss legal aspects of DeepCode’s

The team, led by partner Adrian Dörig (Corporate Finance - pictured) included Peter Kühn (Counsel, Corporate / M&A), Michel Stübi and Florian Angstmann (Associates, Corporate / M&A), Aleksandra Simic (Junior Associate, Corporate / M&A), Christian Wyss (Partner, IP), Jonas Gassmann (Managing Associate, IP) , Marc Ph. Prinz (Partner, Employment), Florian Schaub (Senior Associate, Employment), Christoph Niederer (Partner, Tax) and Patrik Fisch (Associate, Tax).